



Patient Name : Mi Age/Gender : 28

: Mrs.MAMATHA R S

UHID/MR No

: 28 Y 6 M 0 D/F : CBAS.0000090294

Visit ID Ref Doctor : CBASOPV97199 : Dr.SELF

Emp/Auth/TPA ID : 265805

Collected

: 25/Nov/2023 08:29AM

Received : 25/Nov/2023 12:54PM

Reported : 25/Nov/2023 03:48PM Status : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	/ LIEAT TH ANNITAL	DI LIS CHECK	EEMALE - 2D ECHO - E	OVN INDIV - EA3334
ARCOPLINI - INILDIWITELL - FULL BOD	I IILALIII ANNOAL	FLUS CITECK -	PLINALE - 2D ECITO - P	AN INDIA - 1 1 2324
Test Name	Result	Unit	Bio. Ref. Range	Method
I ESLIVALIE	Nesun	UIIIL	BIU. NEI. NAIIUE	METHOR

HAEMOGLOBIN	11.5	g/dL	12-15	Spectrophotometer
PCV	33.70	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.46	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	75.5	fL	83-101	Calculated
MCH	25.7	pg	27-32	Calculated
MCHC	34.1	g/dL	31.5-34.5	Calculated
R.D.W	15.4	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	6,810	cells/cu.mm	4000-10000	Electrical Impedanc
DIFFERENTIAL LEUCOCYTIC COUNT (D	LC)	¥i		
NEUTROPHILS	55.2	%	40-80	Electrical Impedance
LYMPHOCYTES	32.3	%	20-40	Electrical Impedance
EOSINOPHILS	3.7	%	1-6	Electrical Impedance
MONOCYTES	8.7	%	2-10	Electrical Impedance
BASOPHILS	0.1	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3759.12	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2199.63	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	251.97	Cells/cu.mm	20-500	Calculated
MONOCYTES	592.47	Cells/cu.mm	200-1000	Calculated
BASOPHILS	6.81	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	302000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	20	mm at the end of 1 hour	0-20	Modified Westegrer method

RBCs: Show mild anisocytosis with microcytic hypochromic RBCs.

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate.

Page 1 of 16

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE









Patient Name

: Mrs.MAMATHA R S

Age/Gender

: 28 Y 6 M 0 D/F

UHID/MR No

: CBAS.0000090294

Visit ID Ref Doctor : CBASOPV97199

Emp/Auth/TPA ID

: Dr.SELF : 265805

Collected

: 25/Nov/2023 08:29AM

Received

: 25/Nov/2023 12:54PM

Reported Status

: 25/Nov/2023 03:48PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

HEMOPARASITES: negative

IMPRESSION: MICROCYTIC HYPOCHROMIC ANEMIA

Note: Kindly evaluate for iron deficiency status.

Kindly correlate clinically.

Page 2 of 16

SIN No:BED230289226

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mrs.MAMATHA R S Age/Gender

: 28 Y 6 M 0 D/F

UHID/MR No : CBAS.0000090294 Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805

Collected : 25/Nov/2023 08:29AM

Received : 25/Nov/2023 12:54PM Reported : 25/Nov/2023 04:31PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FAC	TOR , WHOLE BLOOD EDTA	
BLOOD GROUP TYPE	0	Microplate Hemagglutination
Rh TYPE	Positive	Microplate Hemagglutination

Page 3 of 16

SIN No:BED230289226

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mrs.MAMATHA R S Age/Gender : 28 Y 6 M 0 D/F

UHID/MR No : CBAS.0000090294 Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805

Collected : 25/Nov/2023 08:29AM

Received : 25/Nov/2023 01:06PM Reported : 25/Nov/2023 01:51PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range Method

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation	
70-100 mg/dL	Normal	
100-125 mg/dL	Prediabetes	700
≥126 mg/dL	Diabetes	
<70 mg/dL	Hypoglycemia	

Note:

1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.

2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 4 of 16

SIN No:PLF02059222 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mrs.MAMATHA R S Age/Gender : 28 Y 6 M 0 D/F

UHID/MR No : CBAS.0000090294 Visit ID : CBASOPV97199

Ref Doctor : Dr.SFLF

Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM

Received : 25/Nov/2023 01:09PM Reported : 25/Nov/2023 03:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, POST PRANDIAL (PP), 2	78	mg/dL	70-140	HEXOKINASE
HOURS , SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.6	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG), WHOLE BLOOD EDTA	114	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.

Page 5 of 16





Patient Name Age/Gender : Mrs.MAMATHA R S

UHID/MR No

: 28 Y 6 M 0 D/F

Visit ID

: CBAS.0000090294 : CBASOPV97199

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 265805

Collected

: 25/Nov/2023 08:29AM

Received

: 25/Nov/2023 01:09PM

Reported

: 25/Nov/2023 03:19PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 16



SIN No:PLP1390473,EDT230105922 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





Patient Name Age/Gender

: Mrs.MAMATHA R S

UHID/MR No

: 28 Y 6 M 0 D/F

: CBAS.0000090294

Visit ID Ref Doctor : CBASOPV97199

Emp/Auth/TPA ID

: Dr.SELF : 265805

Collected

: 25/Nov/2023 08:29AM

Received

: 25/Nov/2023 01:38PM

Reported

Status

: 25/Nov/2023 03:07PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method
TOST HAITIC	Result	Ome	Bio. Rei. Range	Method

L IPID PROFILE , SERUM				
TOTAL CHOLESTEROL	161	mg/dL	<200	CHO-POD
TRIGLYCERIDES	164	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	38	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	123	mg/dL	<130	Calculated
LDL CHOLESTEROL	90.5	mg/dL	<100	Calculated
VLDL CHOLESTEROL	32.8	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.24		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
IINON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 7 of 16

SIN No:SE04549753

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telan www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744 APOLLO CLINICS NETWORK







Patient Name : Mrs.MAMATHA R S Age/Gender : 28 Y 6 M 0 D/F

UHID/MR No : CBAS.0000090294

Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM

Received : 25/Nov/2023 01:38PM Reported : 25/Nov/2023 03:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

IVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.77	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.12	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.65	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	32	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	35.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	66.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.32	g/dL	6.6-8.3	Biuret
ALBUMIN	4.27	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.05	g/dL	2.0-3.5	Calculated
A/G RATIO	1.4		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 8 of 16







Patient Name

: Mrs.MAMATHA R S

Age/Gender

: 28 Y 6 M 0 D/F

UHID/MR No

: CBAS.0000090294

Visit ID Ref Doctor : CBASOPV97199

Emp/Auth/TPA ID

: Dr.SELF : 265805

Collected

: 25/Nov/2023 08:29AM

Received

: 25/Nov/2023 01:38PM

Reported

: 25/Nov/2023 03:07PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

Method

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range

Page 9 of 16

SIN No:SE04549753

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name Age/Gender

: Mrs.MAMATHA R S

: 28 Y 6 M 0 D/F

UHID/MR No

: CBAS.0000090294

Visit ID Ref Doctor : CBASOPV97199

Emp/Auth/TPA ID

: Dr.SELF : 265805

Collected

: 25/Nov/2023 08:29AM

Received

: 25/Nov/2023 01:38PM

Reported

: 25/Nov/2023 03:07PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result	Unit	Bio. Ref. Range	Method
------------------	------	-----------------	--------

CREATININE	0.46	mg/dL	0.72 - 1.18	JAFFE METHOD
UREA	17.30	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	8.1	mg/dL	8.0 - 23.0	Calculated
URIC ACID	4.33	mg/dL	2.6-6.0	Uricase PAP
CALCIUM	8.80	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	3.45	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	137	mmol/L	136–146	ISE (Indirect)
POTASSIUM	4.2	mmol/L	3.5–5.1	ISE (Indirect)
CHLORIDE	103	mmol/L	101–109	ISE (Indirect)

Page 10 of 16

SIN No:SE04549753

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name Age/Gender

: Mrs.MAMATHA R S

UHID/MR No

: 28 Y 6 M 0 D/F

Visit ID

: CBAS.0000090294 : CBASOPV97199

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 265805 Collected

: 25/Nov/2023 08:29AM

Received

: 25/Nov/2023 01:38PM

Reported

: 25/Nov/2023 03:07PM

: Final Report

Status Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GAMMA GLUTAMYL TRANSPEPTIDASE	13.00	U/L	<38	IFCC	
(GGT) . SERUM					

Page 11 of 16

SIN No:SE04549753

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mrs.MAMATHA R S Age/Gender : 28 Y 6 M 0 D/F

UHID/MR No : CBAS.0000090294 Visit ID : CBASOPV97199

: Dr.SELF

Ref Doctor

Emp/Auth/TPA ID

Collected : 25/Nov/2023 08:29AM

Received : 25/Nov/2023 01:38PM Reported : 25/Nov/2023 03:31PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

: 265805

TRI-IODOTHYRONINE (T3, TOTAL)	0.8	ng/mL	0.7-2.04	CLIA	
THYROXINE (T4, TOTAL)	9.20	μg/dL	5.48-14.28	CLIA	
THYROID STIMULATING HORMONE (TSH)	8.164	μIU/mL	0.34-5.60	CLIA	

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 12 of 16

SIN No:SPL23167342

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telang www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744 a - 500 016 | APOLLO CLINICS NETWORK







Patient Name

: Mrs.MAMATHA R S

Age/Gender

: 28 Y 6 M 0 D/F

UHID/MR No

: CBAS.0000090294

Visit ID Ref Doctor : CBASOPV97199

Emp/Auth/TPA ID

: Dr.SELF : 265805 Collected

: 25/Nov/2023 08:29AM

Received

: 25/Nov/2023 02:32PM

Reported

: 25/Nov/2023 04:56PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	6.0		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.010		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MOUNT	AND MICROSCOPY			
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 13 of 16

SIN No:UR2226519

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK







Patient Name Age/Gender

: Mrs.MAMATHA R S

: 28 Y 6 M 0 D/F

UHID/MR No

: CBAS.0000090294

Ref Doctor

Visit ID

: CBASOPV97199

Emp/Auth/TPA ID

: Dr.SELF : 265805

Collected

: 25/Nov/2023 08:29AM

Received

: 25/Nov/2023 01:23PM

Reported Status

: 25/Nov/2023 03:12PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE	Dipstick

		I .	
URINE GLUCOSE(FASTING)	NEGATIVE	NEGATIVE	Dipstick

Page 14 of 16

SIN No:UPP015844,UF009831 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE











Patient Name Age/Gender : Mrs.MAMATHA R S

UHID/MR No

: 28 Y 6 M 0 D/F : CBAS.0000090294

Visit ID Ref Doctor : CBASOPV97199

Emp/Auth/TPA ID

: Dr.SELF : 265805 Collected

: 25/Nov/2023 01:29PM

Received

: 26/Nov/2023 04:20PM

Reported

: 27/Nov/2023 04:59PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

	CYTOLOGY NO.	19768/23
I	SPECIMEN	
a	SPECIMEN ADEQUACY	ADEQUATE
b	SPECIMEN TYPE	LIQUID-BASED PREPARATION (LBC)
	SPECIMEN NATURE/SOURCE	CERVICAL SMEAR
c	ENDOCERVICAL-TRANSFORMATION ZONE	PRESENT WITH ENDOCERVICAL CELLS
d	COMMENTS	SATISFACTORY FOR EVALUATION
Π	MICROSCOPY	Superficial and intermediate squamous epithelial cells with benign morphology.
		Negative for intraepithelial lesion/ malignancy.
II	RESULT	
a	EPITHEIAL CELL	
	SQUAMOUS CELL ABNORMALITIES	NOT SEEN
	GLANDULAR CELL ABNORMALITIES	NOT SEEN
b	ORGANISM	NIL
V	INTERPRETATION	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Pap Test is a screening test for cervical cancer with inherent false negative results. Regular screening and follow-up is recommended (Bethesda-TBS-2014) revised

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

Page 15 of 16

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE











Patient Name

: Mrs.MAMATHA R S

Age/Gender

: 28 Y 6 M 0 D/F

UHID/MR No

: CBAS.0000090294

Visit ID Ref Doctor : CBASOPV97199

Emp/Auth/TPA ID

: Dr.SELF : 265805 Collected

: 25/Nov/2023 01:29PM

Received

: 26/Nov/2023 04:20PM

Reported

: 27/Nov/2023 04:59PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

DR. K. RAMA KRISHNA REDDY M.B.B.S, M.D CONSULTANT PATHOLOGIST DR.SHIVARAJA SHETTY
M.B.B.S,M.D(Biochemistry)
CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist Dr. Chinki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 16 of 16

SIN No:CS070548

This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory, Hyderabad

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





Patient Name : Mrs. Mamatha R S Age/Gender : 28 Y/F

UHID/MR No. Sample Collected on

: CBAS.0000090294

LRN#

: RAD2159463

Ref Doctor Emp/Auth/TPA ID : 265805

: SELF

OP Visit No

Reported on

: CBASOPV97199 : 27-11-2023 10:06

Specimen

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Both lungs fields appears normal and shows normal bronchovascular markings.

Bilateral hila appears normal.

Cardiac silhouette appears normal.

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

IMPRESSION:

No obvious abnormality seen in the present study.

Dr. V K PRANAV VENKATESH

MBBS,MD

Radiology



Name : Mrs. Mamatha R S

Age: 28 Y Sex: F UHID:CBAS.0000090294

Address: blr

Plan

: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN

INDIA OP AGREEMENT

OP Number:CBASOPV97199

Bill No: CBAS-OCR-59140 **Date**: 25.11.2023 08:23

	Department
Sno Serive Type/ServiceName	
Serive Type/ServiceName ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK	- FEMALE - 2D LENG - TAIL THE
1 URINE GLUCOSE(FASTING)	
2 GAMMA GLUTAMYL TRANFERASE (GGT)	
3 HbATc, GLYCATED HEMOGLOBIN	M. Cy
4 2 D ECHO	
-5 LIVER FUNCTION TEST (LFT)	
6X-RAY CHEST PA 124	
7 GLUCOSE, FASTING	
8 HEMOGRAM + PERIPHERAL SMEAR	
_9 ENT CONSULTATION	
10 FITNESS BY GENERAL PHYSICIAN	
11 GYNAECOLOGY CONSULTATION	3
12 DIET CONSULTATION — Z	
13 COMPLETE URINE EXAMINATION	
14 URÎNE GLUCOSE(POST PRANDIAL)	
LS PERTPHERAL SMEAR	3
16 ECG K3.	
.17 BLOOD GROUP ABO AND RH FACTOR	
18 LIPID PROFILE	
19 BODY-MASS INDEX (BMI)	
20 LBC PAP TEST- PAPSURE	
21 OPTHAL BY GENERAL PHYSICIAN	
22 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT) 22 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT) 23 PH TRACCUMD, WHOLE ARDOMEN DE 0:15 Am.	
231UETRASOUND - WHOLE RESOURCE	
24 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	
25 DENTAL CONSULTATION	
26 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	

~>	Physio	-6
•	3 . 5	

Ht - 158 Nt - 8/16 BD - \$14/83 PUT. - 88 ND - 97 Ht - 111.

Dr.Yogesh MD,DNB,I Reg No- K Authoria Report ID: AHLLP_01P3FGAT6Q10YJC_V6Q10YLG ٧4 V5 9/ Sinus Rhythm Regular, Tacycardia with one episode of Sinoatrial Exit Block No Significant ST-T Changes Normal Axis to correlate clinically This trace is generated by KurdioScreen: Cloud-Connected, Portable, Digital, 6-12 Lead Scalable ECG Platform from IMEDRIX Interpretation HR: 125 BPM PR: 137 ms PD: 116 ms QRS: 75 ms QRS Axis: 39 deg QT/QTc: 331/478 ms Measurements **V**2 **V**3 7 Vitals aVR aVL aVF Pre-Existing Medical- Symptoms Conditions Date: IST: 2023-11-25 12:27:17 UHID: 01P3FGAT6QI0YJC PatientID: 90294 Mobile: 8965325412 Personal Details Name: mamatha Gender: Female Age: 28

Speed: 25 mm/sec F: 0.05 - 40 Hz Limb: 10 mm/mV Chest: 10 mm/mV Chest: 10 mm/mV Normal ECG does not always mean severe heart disease Comments & report is based on available data, chinical correlation is important.

Version1.8.2 Copyright (Medius, All R)

PAP SMEAR CONSENT FORM

PATIENT NAME: AGE:	GENDER: DATE: 25 11 23
MENSTRUAL AND REPRODUC	TIVE HISTORY
AGE OF MENARCHE	: 134
AGE OF MENOPAUSAL IF APPLICABLE	
MENSTRUAL REGULARITY	: REGULAR/IRREGULAR
FIRST DAY OF LAST MENSTRUATION PERI	OD: M-11-25.
AGE AT MARRIAGE	: 247.
YEAR'S OF MARRIED LIFE	: 5
CONTRACEPTION	:YES(NO)IF YES WHAT KIND?
HORMONAL TREATMENT	: YES() NO() IF YES WHAT KIND?
GRAVIDA (NO OF TIME'S CONCEIVED)	
PARA(NO OF CHILDBIRTH)	: PIG TO VID: ST
LIVE(NO OF LIVING CHILDREN)	
ABORTIONS	:
MISCARRIAGES/ABORTION	:
AGE OF FIRST CHILD	:
AGE OF LAST CHILD	:
PREVIOUS PAP SMEAR REPORT	:
SPECULUM EXAMINA EXTERNAL GENITALIA	ATION FINDINGS
VAGINA CERVIX SMEAR THAKEN FROM – ENDOCERVIX	crosion (+)
ECTOCERVIX POSTERIOR VAGINA	
HEREBY DECLARE THAT THE ABOVE IN	FORMINFORMATION TRUE I HAVE BEEN EXPLAINED THE

PROCEDURE AND GIVEN MY CONSENT TO UNDERGO THE SAME.

SIGNATURE OF THE PATEINT

SIGNATURE OF THE DOCTOR

RE: Health checkup booking no. 3

Corporate Apollo Clinic <corporate@apolloclinic.com>

Thu 11/23/2023 5:17 PM

Cc:Customer Care :Mediwheel : New Delhi | Customercare@mediwheel.in>;Network : Mediwheel : New Delhi | Customer Care :Mediwheel : New Delhi | Customercare@mediwheel.in>;Network : Mediwheel : New Delhi | Customercare@mediwheel : New Delhi | Custome

Apolloclinic <basavanagudi@apolloclinic.com>

Namaste Team,

Greetings from Apollo Clinics,

ease min be	low appointn		· · · · · · · · · · · · · · · · · · ·			5-8 4 (Jan 1971) - 1 di				18 x 18 1	e at market fee	See S Jane
bobE50590	MS. MATHUR SAPNA	54	S	mathursapna8@gmail.com	9291228661	25-11-2023	9:00 AM	Apollo Spectra Hospital	Telangana	Hyderabad	SPECTRA APOLLO HOSPITAL (A UNIT OF NANO HOSPITALS PVT LTD)	Not Confirmed
bob\$50259	Mamatha r	28	Female	dhanarajprince@gmail.com	9980588916	25-11-2023	9:00 AM	Apollo Clinic Basavanagudi		Bangalore	Apollo Clinic, # 99, Bull Temple Road, Next to Ramakrishna mutt, Basavanagudi, Bengaluru, Karnataka,	Confirmed
bobE50258	MR. NAYAK DHANARAJ DEVANAND	33	3 Male	dhanarajprince@gmail.com	9980588916	25-11-2023	9:00 AM	Apollo Clinic Basavanagudi		Bangalore	Apollo Clinic, # 99, Bull Temple Road, Next to Ramakrishna mutt, Basavanagudi Bengaluru, Karnataka,	Confirme

Thanks & Regards,

Anvesh M| Apollo Clinics | Pan India Toll No: 1860 500 7788| Contact E-Mail: corporate@apolloclinic.com | www.apolloclinic.com |

From: Wellness : Mediwheel : New Delhi <wellness@mediwheel.in>

Sent: 23 November 2023 12:32

Cc: Customer Care : Mediwheel : New Delhi < customercare@mediwheel.in>; Network : Mediwheel : New Delhi < network@mediwheel.in>; deepak

<deepak.c@apolloclinic.com>

Subject: Health checkup booking no. 3

Dear team

Please note the following health checkup booking and confirm the same.

Pleas	e note the following health chec	kup booking a							gar ing transition	Special Control	1.28.	
S.	Company Mame	page, Kritis S projekti	Kodinii 61	grave col	1-38,	rgg to "		117 v - 4-1	1.5	la -		
No.	Arcofemi/Mediwheel/MALE/FEMALE	Arcofemi MediWheel Full Body Annual Plus Check Advanced Female 2D ECHO (Metro)		MS. MATHUR SAPNA	54		mathursapna8@gmail.com	9291228661	25/11/2023		Apollo Spectra Hospital	Telar
		Arcofemi MediWheel Full Body			2	8 Fema	e <u>dhanarajprince@gmail.com</u>	n 998058891	5 25/11/2023	9:00 AM	Apollo Clinic Basavanagudi	
	Arcofemi/Mediwheel/MALE/FEMALI	Arcofemi MediWheel Full Body Annual Plus Male 2D ECHO (Metro)	bobE5025	MR. NAYAK DHANARAJ 8 DEVANAND	3	3 Male	dhanarajprince@gmail.com	<u>m</u> 998058891	6 25/11/2023	9:00 AM	Apollo Clinic Basavanagudi	

Apollo Clinic

CONSENT FORM

Patient Name: Marmatha Age:		••••••	
UHID Number: Company N	ame:		
l Mr/Mrs/Ms Employee of	·		
(Company) Want to inform you that I am not interested in getting	2 D [Echo,	Filmby 9.1
Tests done which is a part of my routine health check package.	•	A 1	
And I claim the above statement in my full consciousness.	Clien	left	Film by 9.1 without Sign
			518
Patient Signature: Date:			



To,

The Coordinator, Mediwheel (Arcofemi Healthcare Limited) Helpline number: 011- 41195959

Dear Sir / Madam,

Sub: Annual Health Checkup for the employees of Bank of Baroda

This is to inform you that the following spouse of our employee wishes to avail the facility of Cashless Annual Health Checkup provided by you in terms of our agreement.

Cashless Annual Health Checkup	JIOVIded by you						
PARTICULARS OF HEALTH CHECK UP BENEFICIARY							
	MAMATHA RS						
NAME	05-06-1995						
DATE OF BIRTH	24-11-2023						
PROPOSED DATE OF HEALTH	24-11 2020						
CHLORO							
SPOUSE	23D180255100074628S						
BOOKING REFERENCE NO.	CROUSE DETAILS						
	MR. NAYAK DHANARAJ DEVANAND						
EMPLOYEE NAME							
EMPLOYEE EC NO.	180255						
EMPLOYEE DESIGNATION	HEAD CASHIER "E"_II						
EMPLOYEE PLACE OF WORK	BANGALORE,GANDHI BAZAR						
EMPLOYEE PLACE OF THE	31-07-1990						
EMPLOYEE BIRTHDATE							

This letter of approval / recommendation is valid if submitted along with copy of the Bank of Baroda employee id card. This approval is valid from 08-11-2023 till 31-03-2024. The list of medical tests to be conducted is provided in the annexure to this letter. Please note that the said health checkup is a cashless facility as per our tie up arrangement. We request you to attend to the health checkup requirement of our employee's spouse and accord your top priority and best resources in this regard. The EC Number and the booking reference number as given in the above table shall be mentioned in the invoice, invariably.

We solicit your co-operation in this regard.


Yours faithfully,

Sd/-

Chief General Manager **HRM Department** Bank of Baroda


(Note: This is a computer generated letter. No Signature required. For any clarification, please contact Mediwheel (Arcofemi Healthcare Limited))





Mrs. Mamatte RS. 28/F 90294 2/1/23

EYE CHECK UP REPORT



- Fundus:
- Read Inetire Evaluation

Be Myopic Asdismatism, Adv Sor dilated netraction & getina svaluation,



mm. Mamalta, 28 Jr.

	M92	Y (,) (,			
Height: 5.3	Weight:	79.m.	BMI :		Waist Circum :
Temp:	Pulse :	U	Resp :		B.P :
General Examination / Allerg History			anagement Plan	Ign.	755-587
Alika 18	Tool	nigh (Tol-lut		20671.
Maus Walis, wh	45.			$\binom{1}{2}$	M-737 W-707
V				oh 3	W-707 W-67
Din, 78		Min,	Ju.	6.	M=64b
				r. Ro	-20 h b himble 193 49333

Follow up date:

Doctor Signature



Patient Name : Mrs. Mamatha R S Age/Gender : 28 Y/F

 UHID/MR No.
 : CBAS.0000090294
 OP Visit No
 : CBASOPV97199

 Sample Collected on
 : 25-11-2023 15:04

Ref Doctor : SELF **Emp/Auth/TPA ID** : 265805

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

<u>Liver:</u> appears normal in size (15.0 cm)and increased in echotexture. No focal lesion is seen. Portal vein and Common Bile Duct appear normal. No dilatation of the intrahepatic biliary radicals.

Gall bladder is well distended. No evidence of calculus. Wall thickness appears normal. No evidence of periGB collection. No evidence of focal lesion is seen.

Spleen appears normal. No focal lesion seen. Splenic vein appears normal.

Pancreas appears normal in echo-pattern. No focal/mass lesion/calcification. No evidence of peripancreatic free fluid or collection. Pancreatic duct appears normal.

Right kidney appear normal in size 11.5x1.6 cm, shape and echopattern. Cortical thickness and Cortico-medullary differentiation are maintained.

Left kidney appear normal in size 10.2x1.5 cm, shape and echopattern. Cortical thickness and Cortico-medullary differentiation are maintained

<u>Urinary Bladder</u> is well distended and appears normal. No evidence of any wall thickening or abnormality. No evidence of any intrinsic or extrinsic bladder abnormality detected.

<u>Uterus</u> appears normal in size and measuring 8.2x4.7x5.0 cm. It shows normal shape & echo pattern. Endometrial echo-complex appears normal and measures 0.7 cm.

Both ovaries appear normal in size, shape and echotexture.

Right ovary measuring 2.5x1.9 cm and left ovary measuring 3.2x1.5 cm volume cc.

No evidence of any adnexal pathology noted.

- No thickened or tender bowel loops. No mass lesion. No ascites / pleural effusion.

IMPRESSION:-

Grade I Fatty Liver.

Suggested clinical correlation.

The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.



Patient Name : Mrs. Mamatha R S Age/Gender : 28 Y/F

Dr. V K PRANAV VENKATESH

MBBS,MD

Radiology

Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 12:54PM Reported : 25/Nov/2023 03:48PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	11.5	g/dL	12-15	Spectrophotometer
PCV	33.70	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.46	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	75.5	fL	83-101	Calculated
MCH	25.7	pg	27-32	Calculated
MCHC	34.1	g/dL	31.5-34.5	Calculated
R.D.W	15.4	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	6,810	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	LC)			
NEUTROPHILS	55.2	%	40-80	Electrical Impedanc
LYMPHOCYTES	32.3	%	20-40	Electrical Impedanc
EOSINOPHILS	3.7	%	1-6	Electrical Impedanc
MONOCYTES	8.7	%	2-10	Electrical Impedanc
BASOPHILS	0.1	%	<1-2	Electrical Impedanc
ABSOLUTE LEUCOCYTE COUNT		,		
NEUTROPHILS	3759.12	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2199.63	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	251.97	Cells/cu.mm	20-500	Calculated
MONOCYTES	592.47	Cells/cu.mm	200-1000	Calculated
BASOPHILS	6.81	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	302000	cells/cu.mm	150000-410000	Electrical impedenc
ERYTHROCYTE SEDIMENTATION RATE (ESR)	20	mm at the end of 1 hour	0-20	Modified Westegrer method

RBCs: Show mild anisocytosis with microcytic hypochromic RBCs.

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate.

Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 12:54PM Reported : 25/Nov/2023 03:48PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HEMOPARASITES: negative

IMPRESSION: MICROCYTIC HYPOCHROMIC ANEMIA

Note: Kindly evaluate for iron deficiency status.

Kindly correlate clinically.



 Patient Name
 : Mrs.MAMATHA R S

 Age/Gender
 : 28 Y 6 M 0 D/F

 UHID/MR No
 : CBAS.0000090294

 Visit ID
 : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 12:54PM Reported : 25/Nov/2023 04:31PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY						
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA					
BLOOD GROUP TYPE	0	Microplate Hemagglutination			
Rh TYPE	Positive	Microplate Hemagglutination			



Patient Name : Mrs.MAMATHA R S Age/Gender : 28 Y 6 M 0 D/F

UHID/MR No : CBAS.0000090294 Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 01:06PM Reported : 25/Nov/2023 01:51PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

GLUCOSE, FASTING, NAF PLASMA	99	mg/dL	70-100	HEXOKINASE
------------------------------	----	-------	--------	------------

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- $2.\ Very\ high\ glucose\ levels\ (>\!\!450\ mg/dL\ in\ adults)\ may\ result\ in\ Diabetic\ Ketoacidosis\ \&\ is\ considered\ critical.$



Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 01:09PM Reported : 25/Nov/2023 03:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324							
ARCOPEINI - INIEDIWHEEL - FULL BODT HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - FAN INDIA - FT2324							
			I				
Result	Unit	Rio Ref Range	Method				
Rooun	J	Dio. Ron Rango	motiloa				
	HEALTH ANNUAL Result	HEALTH ANNUAL PLUS CHECK -	HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - F				

GLUCOSE, POST PRANDIAL (PP), 2	78	mg/dL	70-140	HEXOKINASE
HOURS, SODIUM FLUORIDE PLASMA (2		_		
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.6	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG), WHOLE BLOOD EDTA	114	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.

Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 01:09PM Reported : 25/Nov/2023 03:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM
Received : 25/Nov/2023 01:38PM
Reported : 25/Nov/2023 03:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

LIPID PROFILE , SERUM					
TOTAL CHOLESTEROL	161	mg/dL	<200	CHO-POD	
TRIGLYCERIDES	164	mg/dL	<150	GPO-POD	
HDL CHOLESTEROL	38	mg/dL	40-60	Enzymatic Immunoinhibition	
NON-HDL CHOLESTEROL	123	mg/dL	<130	Calculated	
LDL CHOLESTEROL	90.5	mg/dL	<100	Calculated	
VLDL CHOLESTEROL	32.8	mg/dL	<30	Calculated	
CHOL / HDL RATIO	4.24		0-4.97	Calculated	

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.



 Patient Name
 : Mrs.MAMATHA R S

 Age/Gender
 : 28 Y 6 M 0 D/F

 UHID/MR No
 : CBAS.0000090294

 Visit ID
 : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 01:38PM Reported : 25/Nov/2023 03:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.77	mg/dL	0.3–1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.12	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.65	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	32	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	35.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	66.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.32	g/dL	6.6-8.3	Biuret
ALBUMIN	4.27	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.05	g/dL	2.0-3.5	Calculated
A/G RATIO	1.4		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

 Patient Name
 : Mrs.MAMATHA R S

 Age/Gender
 : 28 Y 6 M 0 D/F

 UHID/MR No
 : CBAS.0000090294

 Visit ID
 : CBASOPV97199

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 265805

Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 01:38PM Reported : 25/Nov/2023 03:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method



Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM

Received : 25/Nov/2023 01:38PM

Reported : 25/Nov/2023 03:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM					
CREATININE	0.46	mg/dL	0.72 – 1.18	JAFFE METHOD	
UREA	17.30	mg/dL	17-43	GLDH, Kinetic Assay	
BLOOD UREA NITROGEN	8.1	mg/dL	8.0 - 23.0	Calculated	
URIC ACID	4.33	mg/dL	2.6-6.0	Uricase PAP	
CALCIUM	8.80	mg/dL	8.8-10.6	Arsenazo III	
PHOSPHORUS, INORGANIC	3.45	mg/dL	2.5-4.5	Phosphomolybdate Complex	
SODIUM	137	mmol/L	136–146	ISE (Indirect)	
POTASSIUM	4.2	mmol/L	3.5–5.1	ISE (Indirect)	
CHLORIDE	103	mmol/L	101–109	ISE (Indirect)	



 Patient Name
 : Mrs.MAMATHA R S

 Age/Gender
 : 28 Y 6 M 0 D/F

 UHID/MR No
 : CBAS.0000090294

 Visit ID
 : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 01:38PM Reported : 25/Nov/2023 03:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

·					
DEPARTMENT OF BIOCHEMISTRY					
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	13.00	U/L	<38	IFCC	

Patient Name : Mrs.MAMATHA R S Age/Gender : 28 Y 6 M 0 D/F

UHID/MR No : CBAS.0000090294

Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 01:38PM Reported : 25/Nov/2023 03:31PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM				
TRI-IODOTHYRONINE (T3, TOTAL)	0.8	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	9.20	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	8.164	μIU/mL	0.34-5.60	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions	
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis	
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.	
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism	
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy	
Low	N	N	N	Subclinical Hyperthyroidism	
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism	
Low	N	High	High	Thyroiditis, Interfering Antibodies	
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes	
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	



Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM

Received : 25/Nov/2023 02:32PM

Reported : 25/Nov/2023 04:56PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (C	UE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.010		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				:
URINE PROTEIN NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR	
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	OUNT AND MICROSCOPY			
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY



 Patient Name
 : Mrs.MAMATHA R S

 Age/Gender
 : 28 Y 6 M 0 D/F

 UHID/MR No
 : CBAS.0000090294

 Visit ID
 : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 08:29AM Received : 25/Nov/2023 01:23PM Reported : 25/Nov/2023 03:12PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

-						
DEPARTMENT OF CLINICAL PATHOLOGY						
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		
JRINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick		
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick		







Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 01:29PM Received : 26/Nov/2023 04:20PM Reported : 27/Nov/2023 04:59PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

LBC PA	P TEST (PAPSURE) , CERVICAL BRUSH SAMPI	LE
	CYTOLOGY NO.	19768/23
I	SPECIMEN	
a	SPECIMEN ADEQUACY	ADEQUATE
b	SPECIMEN TYPE	LIQUID-BASED PREPARATION (LBC)
	SPECIMEN NATURE/SOURCE	CERVICAL SMEAR
c	ENDOCERVICAL-TRANSFORMATION ZONE	PRESENT WITH ENDOCERVICAL CELLS
d	COMMENTS	SATISFACTORY FOR EVALUATION
П	MICROSCOPY	Superficial and intermediate squamous epithelial cells with benign morphology. Negative for intraepithelial lesion/ malignancy.
III	RESULT	
a	EPITHEIAL CELL	
	SQUAMOUS CELL ABNORMALITIES	NOT SEEN
	GLANDULAR CELL ABNORMALITIES	NOT SEEN
b	ORGANISM	NIL
IV	INTERPRETATION	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Pap Test is a screening test for cervical cancer with inherent false negative results. Regular screening and follow-up is recommended (Bethesda-TBS-2014) revised

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR





Patient Name : Mrs.MAMATHA R S

Age/Gender : 28 Y 6 M 0 D/F
UHID/MR No : CBAS.0000090294

Visit ID : CBASOPV97199

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 265805 Collected : 25/Nov/2023 01:29PM Received : 26/Nov/2023 04:20PM Reported : 27/Nov/2023 04:59PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

DR. K. RAMA KRISHNA REDDY M.B.B.S., M.D CONSULTANT PATHOLOGIST

DR.SHIVARAJA SHETTY M.B.B.S,M.D(Biochemistry) CONSULTANT BIOCHEMIST Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist Dr. Chinki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist